Tag #Glp-1 Agonists

Showing 13 to 22 of 22 results

theglobeandmail.com

🌐 75% Global Worthiness

Apr 15, 22:17

Canada Updates Pediatric Obesity Guidelines: Medication, Surgery Now Recommended

Canada's new pediatric obesity guidelines, published in the Canadian Medical Association Journal, recommend weight-loss medication for children as young as 12 and surgery from age 13, marking a significant shift in treatment approaches after nearly two decades.

Canada Updates Pediatric Obesity Guidelines: Medication, Surgery Now Recommended

Canada's new pediatric obesity guidelines, published in the Canadian Medical Association Journal, recommend weight-loss medication for children as young as 12 and surgery from age 13, marking a significant shift in treatment approaches after nearly two decades.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the key changes in Canada's updated pediatric obesity treatment guidelines, and what are their immediate implications for affected children and families?

Canada has updated its treatment guidelines for pediatric obesity after nearly two decades, now recommending weight-loss medication for children as young as 12 and surgery for those 13 and older. This follows the rise of effective GLP-1 receptor agonists like semaglutide.

forbes.com

🌐 85% Global Worthiness

Mar 21, 16:11

Decreased Insurance Coverage for GLP-1 Agonists Amidst Soaring Demand

Between 2024 and 2025, insurance coverage for Ozempic dropped 22%, affecting 1.1 million people, while Zepbound saw a 14% increase in uninsured individuals (4.9 million), despite a 300% rise in Zepbound fills and doubled Ozempic fills since early 2024, highlighting the rising cost of these medicatio...

Decreased Insurance Coverage for GLP-1 Agonists Amidst Soaring Demand

Between 2024 and 2025, insurance coverage for Ozempic dropped 22%, affecting 1.1 million people, while Zepbound saw a 14% increase in uninsured individuals (4.9 million), despite a 300% rise in Zepbound fills and doubled Ozempic fills since early 2024, highlighting the rising cost of these medicatio...

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How do the rising demand and high costs of GLP-1 agonists interact with insurance coverage trends?

The decreased insurance coverage correlates with rising demand for GLP-1 agonists like Ozempic and Zepbound, driven by their weight-loss effects. GoodRx data shows a 300% increase in Zepbound fills and a doubling of Ozempic fills since early 2024. This increase in demand, coupled with high costs (Ozempic: $997.58, Zepbound: $1086.37 per injection pen), creates financial strain for patients.

kathimerini.gr

🌐 85% Global Worthiness

Feb 26, 10:09

GLP-1 Agonist Shows Significant Promise in Treating Obstructive Sleep Apnea

A year-long study published in The New England Journal of Medicine showed that tirzepatide, a GLP-1 agonist, reduced the apnea-hypopnea index by almost 59% in 469 obese individuals with moderate-to-severe obstructive sleep apnea, alongside an average 20% weight loss; this may reduce reliance on CPAP...

GLP-1 Agonist Shows Significant Promise in Treating Obstructive Sleep Apnea

A year-long study published in The New England Journal of Medicine showed that tirzepatide, a GLP-1 agonist, reduced the apnea-hypopnea index by almost 59% in 469 obese individuals with moderate-to-severe obstructive sleep apnea, alongside an average 20% weight loss; this may reduce reliance on CPAP...

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the key mechanisms by which GLP-1 agonists impact obstructive sleep apnea, and what factors contribute to its varying effectiveness among individuals?

This significant reduction in OSA severity is linked to weight loss induced by GLP-1 agonists. Excess weight is a major risk factor for OSA, as fat deposits in the neck and abdomen restrict airways. The study, published in The New England Journal of Medicine, involved 469 obese participants with moderate to severe OSA.

bbc.com

🌐 85% Global Worthiness

Jan 28, 10:06

Kennedy-Oz Clash on Weight-Loss Drug Coverage Looms

The conflicting views of Robert F. Kennedy Jr. and Mehmet Oz on the Trump administration's policy regarding Medicare and Medicaid coverage of costly new weight-loss drugs create uncertainty, impacting millions' access to potentially life-changing medication.

Kennedy-Oz Clash on Weight-Loss Drug Coverage Looms

The conflicting views of Robert F. Kennedy Jr. and Mehmet Oz on the Trump administration's policy regarding Medicare and Medicaid coverage of costly new weight-loss drugs create uncertainty, impacting millions' access to potentially life-changing medication.

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate impacts of the high cost and limited insurance coverage of new weight-loss drugs on patients' access to treatment and overall health outcomes?

The high cost of new weight-loss drugs, averaging \$1,000 per month, and limited insurance coverage create significant access barriers for many patients. Dr. Mollie Cecil's experience exemplifies this, highlighting how loss of coverage led to weight regain. This impacts patient health and raises concerns about equitable access to potentially life-changing medication.

it.euronews.com

🌐 85% Global Worthiness

Jan 21, 01:09

Weight-Loss Drugs Show Reduced Alzheimer's Risk, But Increased Gastrointestinal Issues

A study of over two million US diabetic patients found that GLP-1 receptor agonist weight-loss drugs like Wegovy and Ozempic reduced the risk of Alzheimer's by 12%, drug/alcohol dependence, and some blood clotting issues, but increased risks of gastrointestinal problems, low blood pressure, and kidn...

Weight-Loss Drugs Show Reduced Alzheimer's Risk, But Increased Gastrointestinal Issues

A study of over two million US diabetic patients found that GLP-1 receptor agonist weight-loss drugs like Wegovy and Ozempic reduced the risk of Alzheimer's by 12%, drug/alcohol dependence, and some blood clotting issues, but increased risks of gastrointestinal problems, low blood pressure, and kidn...

Progress

32% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the significant health risks and benefits associated with GLP-1 receptor agonist weight-loss drugs based on the study of over two million patients?

A large-scale study of over two million US diabetic patients revealed that GLP-1 receptor agonist weight-loss drugs, like Wegovy and Ozempic, are associated with a reduced risk of various health issues, including Alzheimer's disease (12% reduction), drug/alcohol dependence, and certain blood clotting problems. However, these drugs also showed increased risks of gastrointestinal problems, low blood pressure, and kidney stones.

dailymail.co.uk

🌐 85% Global Worthiness

Apr 13, 16:11

Sirona Weight-Loss Pill Shows Promising Results in NHS Trial

A new weight-loss pill, Sirona, currently in NHS trials, shows obese patients losing an average of 3.6kg (7.9 lbs), or roughly 10%, of their body weight in 12 weeks with no reported side effects, unlike other treatments like Ozempic and Xenical.

Sirona Weight-Loss Pill Shows Promising Results in NHS Trial

A new weight-loss pill, Sirona, currently in NHS trials, shows obese patients losing an average of 3.6kg (7.9 lbs), or roughly 10%, of their body weight in 12 weeks with no reported side effects, unlike other treatments like Ozempic and Xenical.

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does Sirona's mechanism of action differ from existing weight-loss drugs, and what are the potential benefits and drawbacks based on the current trial data?

This contrasts sharply with existing treatments like Ozempic (semaglutide) and Mounjaro (tirzepatide), which yielded weight loss of 3.6% and 5.9% respectively over similar periods. Sirona's mechanism—filling the stomach with an inert gel—differs significantly, potentially offering a safer alternative.

dailymail.co.uk

🌐 85% Global Worthiness

Mar 11, 04:08

Weight-Loss Drugs Linked to Tripled Depression Risk

A new study reveals that weight-loss drugs like Wegovy, Ozempic, and Saxenda nearly triple the risk of depression in obese patients, alongside other medications including PPIs and beta-blockers, raising concerns about their widespread use and potential mental health effects.

Weight-Loss Drugs Linked to Tripled Depression Risk

A new study reveals that weight-loss drugs like Wegovy, Ozempic, and Saxenda nearly triple the risk of depression in obese patients, alongside other medications including PPIs and beta-blockers, raising concerns about their widespread use and potential mental health effects.

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the critical future implications of these findings for public health policy and pharmaceutical practices regarding medication-induced depression?

The rising use of medications like GLP-1 agonists for obesity treatment necessitates further research into long-term psychiatric consequences. The potential for increased depression and suicidal ideation among large populations necessitates proactive strategies to manage this risk, including comprehensive patient monitoring and alternative treatment options. This is especially crucial given that many patients might not realize the link between their medication and their mental health.

dailymail.co.uk

🌐 85% Global Worthiness

Feb 12, 19:19

Semaglutide Shows Promise in Reducing Alcohol Consumption

A US study found that semaglutide injections reduced alcohol consumption by 41% in 48 adults with alcohol use disorder over nine weeks, suggesting a potential new treatment; however, further research is needed.

Semaglutide Shows Promise in Reducing Alcohol Consumption

A US study found that semaglutide injections reduced alcohol consumption by 41% in 48 adults with alcohol use disorder over nine weeks, suggesting a potential new treatment; however, further research is needed.

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of the study's findings on potential treatments for alcohol use disorder?

A new study suggests that semaglutide, the active ingredient in weight-loss drugs Wegovy and Ozempic, may significantly reduce alcohol consumption. In a nine-week trial involving 48 adults with alcohol use disorder, those receiving semaglutide injections experienced a 41% reduction in alcohol intake compared to a placebo group. This finding offers a potential new treatment for alcohol use disorder.

fr.euronews.com

🌐 85% Global Worthiness

Jan 21, 10:09

Weight-Loss Drugs Show Promise in Treating Multiple Diseases, but Risks Remain

A Nature Medicine study shows weight-loss drugs like Wegovy and Ozempic effectively treat various diseases by reducing obesity and inflammation, potentially lowering Alzheimer's risk by 12%, but also carry risks of gastrointestinal issues, hypotension, and kidney problems.

Weight-Loss Drugs Show Promise in Treating Multiple Diseases, but Risks Remain

A Nature Medicine study shows weight-loss drugs like Wegovy and Ozempic effectively treat various diseases by reducing obesity and inflammation, potentially lowering Alzheimer's risk by 12%, but also carry risks of gastrointestinal issues, hypotension, and kidney problems.

Progress

24% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How do the findings of this study challenge previous understandings of obesity and its treatment?

The study highlights the dual mechanism of GLP-1 receptor agonists: reducing obesity, a risk factor for many diseases, and directly decreasing inflammation, which affects brain reward signals, impulse control, and blood circulation. This broad impact suggests potential benefits across several health areas, including neurocognitive disorders.

elpais.com

🌐 85% Global Worthiness

Dec 2, 10:35

El auge de fármacos contra la obesidad reduce las cirugías bariátricas en Estados Unidos

El uso de agonistas del receptor GLP-1 para tratar la obesidad aumentó un 123% en Estados Unidos entre 2022 y 2023, mientras que las cirugías bariátricas disminuyeron un 25%, planteando un cambio en las estrategias terapéuticas y la necesidad de evaluar la combinación de ambos tratamientos.

El auge de fármacos contra la obesidad reduce las cirugías bariátricas en Estados Unidos

El uso de agonistas del receptor GLP-1 para tratar la obesidad aumentó un 123% en Estados Unidos entre 2022 y 2023, mientras que las cirugías bariátricas disminuyeron un 25%, planteando un cambio en las estrategias terapéuticas y la necesidad de evaluar la combinación de ambos tratamientos.

Progress

40% Bias Score

ShareSaveArticle

12345678

Previous 1 of 8 Next

¿Cuál es el mecanismo de acción de los agonistas del receptor GLP-1 y cómo difiere de la cirugía bariátrica en el tratamiento de la obesidad?

El aumento en el uso de agonistas GLP-1 se debe a su eficacia en la pérdida de peso (alrededor del 15%) y su mecanismo de acción que imita las hormonas de saciedad. Este cambio refleja una evolución en la comprensión de la obesidad y la búsqueda de tratamientos menos invasivos.

Showing 13 to 22 of 22 results